SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 2456988
• 负责人: DEREK RAGHAVAN
• 金额: $ 16.05万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-02-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2456988
• 关键词: antineoplastics; bleomycin; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; female reproductive system neoplasm; fludarabine; gastrointestinal neoplasms; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; leukemia; lung neoplasms; lymphoma; meeting /conference /symposium; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pancreas neoplasms; pathology; prognosis; prostate neoplasms; quality of life; sarcoma; tamoxifen; tissue resource /registry; urinary tract neoplasms; women's health

The USC/Norris Comprehensive Cancer Center began participating in the research activities of the Southwest Oncology Group (SWOG) in 1987 and became a newly funded member institution in 1992. Our participation over the past five years has been characterized by steadily increasing administrative and scientific contributions (consistently ranking in the 2nd-to-3rd quartile among SWOG institutions) and patient accrual (current ranking, 3rd quartile). This has been achieved through the strong support of our Cancer Center which organized and developed several disease-based clinical research programs, provided essential core support for protocol administration, data management, quality assurance monitoring and investigational pharmacy, and implemented an NCI-approved (and grant supplemented) plan to augment the accrual of women and minorities to both intramural and SWOG clinical trials. The disease-based orientation of our Center has allowed SWOG protocols to have a high priority in our Gastrointestinal (GI), Genitourinary (GU), Breast, Hematology/Retroviral and Experimental Therapeutics programs leading to the steady growth in our SWOG patient accrual. In turn, SWOG has been the vehicle through which a growing number of our faculty have been able to bring Center-supported pilot studies and translational research efforts to a national cooperative group. Examples of these latter interactions include our GI Program (members serve as Vice- Chairman SWOG GI Committee, coordinate several SWOG GI protocols and serve as PI of two SWOG U01 grants), GU Program (Program leader serves as principal coordinator of national high-priority neoadjuvant MVAC bladder trial, members participate in funded UCOP and support our designation as a major PCPT study site) and Experimental Therapeutics Program (two highly promising regimens have been adopted into group-wide protocols, SWOG 9509 and 8835). The mutual benefit of this interaction is further reflected by the fact that 15 newly recruited USC faculty in eight different departments or divisions (GI Surgery, Surgical Oncology, Urology, Radiation Oncology, Pathology, Pulmonary Medicine, Hematology, and Oncology) have become SWOG members over the past three years. Despite major challenges from managed care in Southern California and diminished support for public health care facilities such as the USC/Los Angeles County Hospital over the past several years, our SWOG activities have grown. We therefore renew our commitment to SWOG research activities with confidence and the expectation of continued growth in patient and minority accrual, CGOP affiliates and administrative/ scientific leadership in several disease-focused areas.

南加州大学/诺里斯综合癌症中心开始参与 1987 年西南肿瘤学组 (SWOG) 的研究活动 1992年成为新资助的会员机构。我们的参与 过去五年的特点是稳步增长 行政和科学贡献（一直排名在 SWOG 机构中第二至第三四分位数）和患者​​应计情况 （当前排名，第三四分位）。 这是通过以下方式实现的 我们癌症中心的大力支持，组织和发展了 一些基于疾病的临床研究项目，提供了必要的 协议管理、数据管理、质量的核心支持 保证监测和研究药房，并实施了 NCI 批准的（和补助金补充的）计划，以增加应计费用 女性和少数族裔参加壁内和 SWOG 临床试验。这 我们中心基于疾病的导向使 SWOG 协议能够 在我们的胃肠道 (GI)、泌尿生殖系统 (GU) 中具有高度优先权， 乳腺、血液学/逆转录病毒和实验治疗项目 导致我们的 SWOG 患者数量稳定增长。 反过来，SWOG 已经成为我们越来越多的教职人员所使用的工具 能够带来中心支持的试点研究和转化 国家合作小组的研究工作。 这些例子 后者的互动包括我们的地理标志计划（成员担任副主席） SWOG GI 委员会主席，协调多个 SWOG GI 协议并 担任两项 SWOG U01 资助项目的 PI）、GU 项目（项目负责人担任 作为国家高优先级新辅助 MVAC 的主要协调员 膀胱试验，成员参与资助的 UCOP 并支持我们 指定为主要 PCPT 研究中心）和实验治疗学 计划（两种非常有前途的方案已被全集团采用 协议、SWOG 9509 和 8835）。 这种互动的互惠互利 南加州大学新聘任的 15 名教员进一步反映了这一事实： 八个不同的科室或科室（胃肠外科、肿瘤外科、 泌尿科、放射肿瘤科、病理科、肺科、血液科、 和肿瘤学）在过去三年中已成为 SWOG 成员。 尽管南加州的管理式医疗面临着重大挑战， 对南加州大学/洛杉矶分校等公共医疗机构的支持减少 安吉利斯县医院在过去几年中，我们的 SWOG 活动 已经成长了。 因此，我们重申对 SWOG 研究的承诺 充满信心地开展活动并期望持续增长 患者和少数族裔应计费用、CGOP 附属机构和行政/ 在几个疾病重点领域的科学领导地位。